-
-
-
-
-
-
-
Adamas Pharma (ADMS) announces FDA filing acceptance of sNDA to modify indication statement for GOCOVRI to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF
-
-
-
-
-
-
-
Adamas Reports Inducement Grant to New Chief Financial Officer
-
-
-
-
-
-
-
Adamas to Present at Two Upcoming Investor Conferences
-
-
-
-
-
-
-
Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102
-
-
-
-
-
-
-
Adamas Pharmaceuticals (ADMS) Remains Top Pick at Mizuho Into August 24 PDUFA
-
-
-
-
-
-
-
Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

